NCT03964493View on ClinicalTrials.gov

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 20, 2019

Primary Completion Date

September 28, 2020

Study Completion Date

September 28, 2020

Conditions
Skin and Subcutaneous Tissue Bacterial InfectionsGram-Positive Bacterial Infections
Interventions
DRUG

TNP-2092

TNP-2092 100mg/vial

DRUG

Vancomycin

Vancomycin 1g/vial

Trial Locations (1)

92120

eStudy Site, San Diego

All Listed Sponsors
lead

TenNor Therapeutics Limited

INDUSTRY

NCT03964493 - TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection | Biotech Hunter | Biotech Hunter